highli
pathogen
influenza
virus
consid
potenti
influenza
pandem
progenitor
march
laboratoryconfirm
case
infect
report
human
result
death
ie
mortal
rate
http
wwwwhoint
global
mortal
rate
highli
pathogen
pandem
strain
caus
spanish
flu
sever
modern
influenza
pandem
least
first
wave
pandem
suffici
amount
adequ
vaccin
avail
therefor
antivir
therapi
influenza
virus
includ
highli
pathogen
viru
strain
remain
great
import
first
line
defenc
viru
neuraminidas
inhibitor
oseltamivir
zanamivir
well
adamantan
amantadin
rimantadin
interfer
influenza
protein
licens
treatment
influenza
howev
use
drug
class
limit
emerg
resist
viru
strain
season
influenza
strain
major
virus
great
proport
virus
human
consid
amantadin
rimantadineresist
moreov
drastic
increas
oseltamivirresist
virus
report
influenza
season
northern
hemispher
preliminari
data
unit
state
predict
rise
season
possibl
result
circul
strain
oseltamivir
resist
viru
strain
appear
gener
less
sensit
antivir
treatment
season
influenza
viru
strain
treatmentresist
strain
emerg
moreov
parenter
agent
treatment
serious
ill
patient
miss
glycyrrhizin
triterpen
saponin
constitu
licoric
root
found
interfer
replic
andor
cytopathogen
effect
cpe
induct
mani
virus
includ
respiratori
virus
respiratori
syncyti
viru
sar
coronaviru
influenza
virus
moreov
antiinflammatori
immunomodulatori
properti
attribut
glycyrrhizin
sever
human
diseas
associ
hypercytokinaemia
cytokin
storm
delay
antivir
plu
immunomodul
treatment
reduc
mortal
mice
therefor
antiinflammatori
immunomodulatori
effect
exert
glycyrrhizin
may
benefici
treatment
effect
macrophag
thought
contribut
pathogen
alveolar
macrophag
describ
target
cell
human
anim
model
infect
macrophag
result
higher
express
proinflammatori
cytokin
season
influenza
pandem
strain
increas
cytokin
express
implic
contribut
unusu
sever
diseas
therefor
investig
influenc
approv
parenter
glycyrrhizin
formul
stronger
neominophagen
c
snmc
replic
cytokin
express
human
monocytederiv
macrophag
mdm
glycyrrhizin
stronger
neominophagen
c
obtain
minophagen
pharmaceut
co
ltd
tokyo
japan
influenza
strain
receiv
influenza
centr
nation
institut
medic
research
london
uk
influenza
strain
obtain
prof
pilaipan
puthavathana
mahidol
univers
bangkok
thailand
viru
stock
prepar
infect
vero
cell
african
green
monkey
kidney
atcc
manassa
va
aliquot
store
viru
titr
determin
tissu
cultur
infecti
dose
confluent
vero
cell
microtit
plate
human
monocyt
isol
buffi
coat
healthi
donor
obtain
institut
transfus
medicin
immun
haematolog
german
red
cross
blood
donor
center
johann
wolfgang
goetheunivers
frankfurt
main
centrifug
ficol
biocol
densiti
gradient
biochrom
ag
berlin
germani
mononuclear
cell
collect
interfac
wash
pb
monocyt
isol
use
magnet
label
microbead
miltenyi
biotec
gmbh
bergischgladbach
germani
follow
manufactur
instruct
monocyt
cultiv
imdm
supplement
pool
human
serum
iuml
penicillin
streptomycin
monocyt
differenti
monocytederiv
macrophag
stimul
granulocytemacrophag
coloni
stimul
factor
gmcsf
uml
within
day
ident
matur
mdm
confirm
stain
high
express
monocyt
low
express
macrophag
low
express
monocyt
high
express
macrophag
low
express
monocyt
high
express
macrophag
hladr
low
express
monocyt
high
express
macrophag
use
flow
cytometri
antibodi
purchas
bd
bioscienc
heidelberg
germani
confirm
phagocytot
activ
mdm
cell
incub
fluoresc
latex
bead
fluospher
invitrogen
karlsruh
cellular
fluoresc
examin
shown
human
peripher
blood
mononuclear
cell
pbmc
isol
blood
healthi
volunt
centrifug
freshli
isol
pbmc
incub
h
allow
adher
monocyt
bottom
cultur
flask
cell
suspens
collect
natur
killer
nk
cell
separ
accord
manufactur
protocol
use
mac
nk
cell
isol
kit
ii
miltenyi
biotec
bergischgladbach
germani
separ
nk
cell
treat
uml
recombin
human
interleukin
il
cell
concept
umkirch
germani
day
flow
cytometr
analysi
determin
puriti
nk
cell
show
cell
data
shown
antibodi
direct
miltenyi
biotec
bergischgladbach
germani
hladr
three
bd
bioscienc
heidelberg
germani
use
detect
protein
express
monocyt
mdm
flow
cytometri
phycoerythrin
pe
conjug
monoclon
antibodi
mab
direct
nk
cell
surfac
receptor
obtain
miltenyi
biotec
bergischgladbach
germani
peconjug
mab
direct
perforin
granzym
b
purchas
abcam
cambridg
uk
cellular
viabil
assess
confluent
cell
layer
luminesc
cell
viabil
assay
promega
gmbh
mannheim
germani
accord
manufactur
protocol
cell
viabil
express
percentag
nontreat
control
cell
fix
acetonemethanol
min
detect
influenza
nucleoprotein
monoclon
antibodi
msx
influenza
millipor
molsheim
franc
use
primari
antibodi
secondari
antibodi
alexa
fluor
goat
antimous
igg
h
l
invitrogen
eugen
oregon
usa
use
h
incub
pb
nuclei
stain
use
dapi
sigmaaldrich
chemi
gmbh
munich
germani
fluoresc
visualis
use
olympu
ix
fluoresc
microscop
olympu
planegg
germani
cytopathogen
effect
cpe
reduct
assay
perform
describ
confluent
cell
monolay
grown
microtitr
plate
infect
influenza
strain
presenc
absenc
investig
agent
virusinduc
cpe
record
postinfect
pi
use
invert
light
microscop
infecti
viru
titr
determin
describ
briefli
mdm
infect
influenza
multipl
infect
moi
express
mem
supplement
fb
iuml
penicillin
streptomycin
h
aliquot
supernat
taken
serial
dilut
step
perform
infect
determin
endpoint
dilut
titrat
onto
vero
cell
microtitr
plate
plate
incub
day
infect
analys
virusinduc
cytopathogen
effect
viru
titr
calcul
method
reed
muench
viru
titr
mdm
infect
moi
rang
clearli
lower
titr
detect
lung
epitheli
cell
although
cell
type
cell
infect
postinfect
caspas
activ
measur
use
caspaseglo
assay
promega
mannheim
germani
follow
manufactur
instruct
total
rna
isol
cell
cultur
use
tri
reagent
sigmaaldrich
munich
germani
realtim
pcr
perform
use
describ
method
follow
primer
use
sens
acg
tat
gac
tac
ccg
cag
tat
tca
g
antisens
aga
cca
gci
acc
atg
att
gc
probe
aca
gtg
gcg
agt
tcc
cta
gcatamra
investig
express
follow
primer
use
sens
gag
cct
cag
cag
agg
aac
c
antisens
gag
tca
gaa
aga
taa
ggc
agc
investig
taqman
gene
express
assay
appli
biosystem
darmstadt
germani
use
cell
cultur
supernat
collect
frozen
cytokineschemokin
quantifi
specif
elisa
duo
set
r
system
gmbh
wiesbaden
germani
follow
manufactur
instruct
cytotox
nk
cell
determin
h
coupl
luminesc
method
use
acellatox
kit
cell
technolog
mountain
view
ca
usa
describ
cell
use
target
cell
much
cell
cocultur
nk
cell
h
nk
cell
alon
cell
use
control
supernat
collect
test
product
amount
determin
use
quantikin
human
elisa
kit
r
system
wiesbaden
germani
accord
manufactur
protocol
glycyrrhizin
concentr
affect
macrophag
viabil
data
shown
moreov
glycyrrhizin
concentr
neither
reduc
number
macrophag
indic
nucleoprotein
stain
titr
fig
glycyrrhizin
inhibit
moi
induc
caspas
activ
postinfect
fig
noninfect
cell
caspas
activ
affect
investig
glycyrrhizin
concentr
shown
glycyrrhizin
interf
moi
induc
express
cytokin
determin
postinfect
elisa
fig
quantit
pcr
fig
glycyrrhizin
influenc
cytokin
express
noninfect
cell
shown
control
influenza
virusinduc
hypercytokinaemia
may
benefici
diseas
outcom
inhibit
activ
cytotox
cell
control
viru
replic
like
nk
cell
may
harm
therefor
investig
influenc
glycyrrhizin
nk
cell
activ
fig
glycyrrhizin
concentr
influenc
nk
cell
viabil
data
shown
contrast
antivir
drug
ribavirin
shown
inhibit
nk
cell
activ
glycyrrhizin
affect
nk
cell
cytolyt
activ
fig
concord
glycyrrhizin
neither
interfer
nk
cell
surfac
express
activ
receptor
nk
cell
express
perforin
granzym
b
data
shown
investig
influenc
glycyrrhizin
replic
highli
pathogen
influenza
viru
apoptosi
express
proinflammatori
cytokin
human
mdm
well
nk
cell
activ
notabl
cytokin
express
reduc
investig
glycyrrhizin
concentr
although
replic
affect
glycyrrhizin
significantli
inhibit
express
mrna
well
protein
level
increas
level
found
patient
correl
poor
outcom
moreov
induc
significantli
higher
level
mdm
season
influenza
strain
glycyrrhizin
also
significantli
reduc
caspas
activ
intraven
administr
achiev
plasma
concentr
glycyrrhizin
describ
therefor
glycyrrhizin
concentr
found
effect
reduc
proinflammatori
gene
express
present
report
rang
therapeut
plasma
level
experiment
result
previous
suggest
glycyrrhizin
might
abl
affect
season
influenza
viru
diseas
antivir
immunomodulatori
effect
mice
prevent
lethal
infect
glycyrrhizin
although
influenc
viru
replic
detect
mechan
suggest
induct
cell
glycyrrhizin
recent
report
glycyrrhizin
reduc
titr
lungderiv
cell
observ
antivir
activ
glycyrrhizin
assum
mediat
interact
cell
membran
possibl
result
reduc
endocytot
activ
viru
uptak
howev
investig
concentr
clearli
rang
therapeut
plasma
level
concentr
use
us
therefor
hard
compar
result
present
also
antivir
activ
glycyrrhizin
may
differ
season
highli
pathogen
influenza
virus
addit
glycyrrhizinmedi
influenc
may
vari
differ
cell
type
studi
report
first
time
effect
glycyrrhizin
influenza
virus
macrophag
season
influenza
epidem
immunocompromis
young
elderli
person
mostli
affect
contrast
high
death
rate
healthi
complet
immunocompet
individu
report
characterist
diseas
caus
highli
pathogen
pandem
strain
recent
isol
strain
find
suggest
immunemedi
process
may
contribut
highli
pathogen
influenza
viruscaus
patholog
sinc
proinflammatori
gene
express
macrophag
thought
contribut
pathogen
antiinflammatori
effect
glycyrrhizin
macrophag
may
relev
diseas
cours
although
suppress
cytokin
express
alon
appear
suffici
improv
diseas
outcom
control
excess
inflamm
shown
exert
benefici
effect
combin
antivir
treatment
reduc
viru
load
signific
improv
surviv
rate
surviv
time
inflammatori
marker
report
mice
treat
tripl
therapi
contain
zanamivir
immunomodul
includ
celecoxib
mesalazin
comparison
zanamivir
alon
although
zanamivir
without
immunomodul
reduc
viral
load
similar
extent
context
glycyrrhizin
repres
potenti
addit
treatment
option
interfer
express
proinflammatori
cytokin
macrophag
nevertheless
interfer
proinflammatori
respons
remain
doubleedg
sword
one
hand
control
hypercytokinaemia
right
time
point
may
improv
diseas
outcom
hand
global
inhibit
immun
respons
may
also
result
loss
control
viru
replic
cytotox
immun
cell
includ
nk
cell
cytotox
tlymphocyt
concord
global
immunosuppress
like
corticosteroid
fail
protect
lethal
influenza
viru
infect
peroxisom
proliferatoractiv
receptor
agonist
suppress
influenza
virusinduc
express
proinflammatori
chemokin
without
affect
cell
cytotox
activ
protect
mice
lethal
infect
also
antivir
drug
may
interfer
cytotox
cell
control
viru
replic
demonstr
ribavirin
shown
hamper
nk
cell
cytolyt
activ
therefor
abil
glycyrrhizin
interfer
hypercytokinaemia
concentr
affect
nk
cell
activ
may
favour
use
complementari
addit
antiinfluenza
treatment
option
conclus
show
therapeut
concentr
clinic
approv
parenter
prepar
glycyrrhizin
interfer
highli
pathogen
influenza
virusinduc
proinflammatori
gene
express
human
mdm
without
affect
nk
cell
activ
known
involv
control
influenza
viru
replic
vaccin
antivir
agent
fail
meet
global
need
case
sever
influenza
viru
pandem
antiinflammatori
immunomodulatori
agent
import
candid
constitu
antiinfluenza
treatment
strategi
may
save
live
influenza
pandem
situat
therefor
glycyrrhizin
may
complement
arsen
potenti
drug
treatment
diseas
